Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

CAMBRIDGE, Mass., May 15, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that th... Biopharmaceuticals, FDA Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news